CompletedPhase 4

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

United States10 participantsStarted 2012-06

Plain-language summary

The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Be a patient with a confirmed diagnosis of cystinuria. * Be already taking a CBTD (either D-penicillamine (Cuprimine®) or tiopronin (Thiola®) as part of your medication regimen. * Be between 18 and 80 years of age * Be enrolled in the Cystinuria Registry. Exclusion Criteria: * You are not a patient with cystinuria * You are not already taking a cystine binding thiol drug * You have renal colic (if you are passing a stone) * You are scheduled to undergo a urologic procedure * You are unwilling or unable to provide informed consent in order to be able to participate.

What they're measuring

Cystine Capacity

Timeframe: 4 weeks on assigned therapy

Trial details

NCT IDNCT02125721

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-12

Results submitted2019-07-17

View on ClinicalTrials.gov More Cystinuria trials